Welcome to our dedicated page for ZyVersa Therapeutics SEC filings (Ticker: ZVSA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking a clinical-stage biotech like ZyVersa Therapeutics (ZVSA) means sorting through pages of trial data, licensing clauses and cash-runway footnotes. Those details hide in 10-Ks, 10-Qs and rapid-fire 8-Ks—and missing one update could upend a valuation model. Stock Titan pulls every ZyVersa insider trading Form 4 transactions notice, each lab milestone buried in an 8-K and the latest ZyVersa quarterly earnings report 10-Q filing into one constantly refreshed dashboard.
Our AI engine reads every paragraph the moment it hits EDGAR, then delivers plain-English answers to questions investors actually ask: "Is burn rate accelerating?", "Which directors just filed a ZyVersa Form 4 insider transactions real-time?", "What new risk factors surfaced in the ZyVersa annual report 10-K simplified?". You’ll also find annotated sections that map trial expenses to pipeline stages, highlight royalty obligations, and decode the ZyVersa proxy statement executive compensation so you can compare R&D spend to management incentives without scrolling through dense footnotes.
Whether you need ZyVersa 8-K material events explained before the market opens, a ZyVersa earnings report filing analysis for your model, or help understanding ZyVersa SEC documents with AI, Stock Titan’s platform covers every form type: real-time Form 4 alerts, condensed 10-Q summaries, deep-dive 10-K analytics, and side-by-side trend charts. Skip the PDF hunt—get the trial timelines, patent updates and ZyVersa executive stock transactions Form 4 data that drive biotech valuations in minutes, not hours.
ZyVersa Therapeutics announced a leadership change. On October 10, 2025, Pablo Guzman, M.D., resigned as Chief Medical Officer and Senior Vice President of Medical Affairs. Dr. Guzman joined the company in January 2015 after more than 35 years practicing interventional cardiology in South Florida and serving as a managing partner of Cardiology Associates of Fort Lauderdale. The company states he resigned to spend more time with his family and to travel.
ZyVersa Therapeutics, Inc. (ZVSA) submitted a Form 25 notice indicating removal of its securities from listing and/or registration on the Nasdaq Stock Market LLC. The filing identifies the issuer's principal office in Weston, Florida, and provides a contact telephone number. The form lists the regulatory provisions for voluntary or exchange-initiated delisting under 17 CFR 240.12d2-2 and certifies Nasdaq's compliance with the rule for striking the class from listing and/or registration.
FAQ
What is the current stock price of ZyVersa Therapeutics (ZVSA)?
What is the market cap of ZyVersa Therapeutics (ZVSA)?
